Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Cholangiocarcinoma 2Sarcoma 1Recurrence 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 20Fluorouracil 14Cisplatin 10Capecitabine 10Leucovorin 8durvalumab 6Oxaliplatin 6Erlotinib Hydrochloride 4Sorafenib 3Radiotherapy 3trifluridine tipiracil drug combination 2trametinib 2regorafenib 2pembrolizumab 2olaparib 2ceralasertib 2Specimen Handling 2Radiosurgery 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Magnetic Resonance Spectroscopy 2Lapatinib 2Irinotecan 2Filgrastim 2AZD 6244 2zimberelimab 1tremelimumab 1titanium silicide 1tislelizumab 1tegafur-gimeracil-oteracil 1seribantumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bile Duct Neoplasms × Yttrium-90 × Clear all
NCT05655949 2026-04-22

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Beth Israel Deaconess Medical Center

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡